ahlam1399
06-28-2016, 10:45 AM
Roche anticipates quicker U.S. approval for new MS drug
ZURICH (Reuters) - Roche's new multiple sclerosis (MS) drug could be approved in the United States this year, earlier than previously forecast, the Swiss drugmaker said on Tuesday, after winning the U.S. regulator's priority review status for the medicine.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=w44XLVrdKl8:rreUmxcKP3A:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=w44XLVrdKl8:rreUmxcKP3A:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=w44XLVrdKl8:rreUmxcKP3A:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=w44XLVrdKl8:rreUmxcKP3A:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=w44XLVrdKl8:rreUmxcKP3A:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/w44XLVrdKl8
ZURICH (Reuters) - Roche's new multiple sclerosis (MS) drug could be approved in the United States this year, earlier than previously forecast, the Swiss drugmaker said on Tuesday, after winning the U.S. regulator's priority review status for the medicine.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=w44XLVrdKl8:rreUmxcKP3A:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=w44XLVrdKl8:rreUmxcKP3A:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=w44XLVrdKl8:rreUmxcKP3A:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=w44XLVrdKl8:rreUmxcKP3A:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=w44XLVrdKl8:rreUmxcKP3A:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/w44XLVrdKl8